FDA warns Initiative Foods, a Sanger, California baby food maker, that it failed to control patulin, a mold toxin, in fruit pouches.
What happened
FDA inspected the ready-to-eat food plant in Sanger, California from March 31 to April 9, 2026, and issued a list of inspection observations (an FDA-483) at the close; the company had not responded by the time of this letter. FDA found the company's hazard analysis did not treat patulin, a mold toxin common in apples, as a hazard needing a control, and that patulin results on ingredient certificates of analysis (COAs) were not documented as reviewed. The letter notes the company recalled "Tippy Toes" brand Apple Pear Banana puree in February 2026 after an FDA Total Diet Study sample showed elevated patulin, and the company's own testing then found 40 ppb in one lot.
What FDA found
The company's hazard analysis did not identify patulin, a mold toxin found in apples, as a hazard that needed a preventive control in its fruit and vegetable pouches.
21 CFR 117.130(a)(1)The company had not set preventive controls, such as patulin limits for incoming ingredients, for the ingredients used to make its baby food.
21 CFR 117.135(c)The company received certificates of analysis showing patulin levels for some incoming ingredients, but nothing shows these were reviewed as a preventive control.
21 CFR 117.135(a)(1)On December 26, 2025, the company used an ingredient lot whose certificate of analysis had no patulin test results, and nothing shows the gap was caught or addressed before use.
What FDA wants
FDA asks the company to write within 15 working days describing the specific steps taken to fix each violation, with supporting documents, and to explain how it will prevent recurrence. If corrective actions cannot be finished in that time, the company must give the reason and a completion date.
Who should pay attention
- brands that buy baby food pouches from contract manufacturers
- retailers selling store-brand baby food and puree pouches
- fruit and apple ingredient suppliers who issue patulin certificates of analysis
This is a summary. Read the original letter on fda.gov.